Atlas Trials

Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)

Clinical trial NCT00862836 · TERMINATED

Trial details

NCT number
NCT00862836
Sponsor
Genzyme, a Sanofi Company
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Ovarian Cancer
Start date
2009-04-01
Primary completion
2010-09-01
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.